Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

visceral leishmaniasis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

visceral leishmaniasis

MONDO:0005445

Also known as:infection by visceral leishmaniasiskala-azarviscus leishmaniasis

Find Clinical TrialsTrials

Overview

A severe form of leishmaniasis characterized by irregular bouts of fever, substantial weight loss, swelling of the spleen and liver, and anemia (which may be serious). If left untreated it may lead to death. Two species of Leishmania are known to give rise to the visceral form of the disease. The species commonly found in East Africa and the Indian subcontinent is L. donovani and the species found in Europe, North Africa, and Latin America is L. infantum, also known as L. chagasi.

Treatments1 FDA approved

Clinical Trials10 registered · 5 recruiting

Diagnosis

Biomarker and diagnostic research for visceral leishmaniasis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for visceral leishmaniasis, including AMPHOTERICIN B (AMBISOME, approved 1997). An additional 3 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

10 clinical trials registered, 5 recruiting. Interventions under study include other interventions, drug therapy, and medical devices. Pipeline includes 1 PHASE2, 2 NA. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT04020536](https://clinicaltrials.gov/study/NCT04020536)

Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 1:00 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of AMBISOME for managing visceral leishmaniasis?
→Are any of the 10 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
corifungin	corifungin	Sandler Center for Drug Discovery	2011	—	Designated
aminosidine	aminosidine	The Institute for One World Health	2005	—	Designated
Allopurinol riboside	Allopurinol riboside	Burroughs Wellcome Company	1985	—	Withdrawn

Research Type	Count	% of Total
Disease patterns and progression	88	26%
Research summaries	82	24%
Laboratory research	61	18%
Patient case studies	38	11%
Testing and diagnosis research	26	8%
New treatment approaches	21	6%
Other research	11	3%
Clinical study results	11	3%

Kisho

visceral leishmaniasis

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Visceral Leishmaniasis-Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn's Disease in Therapy With Anti-TNFα: A Challenging Diagnostic Case Report.

[Visceral leishmaniasis with suspected autoimmune disease: A report of 2 cases].

Visceral leishmaniasis in a multiple sclerosis patient: a rare complication of fingolimod-induced lymphopenia.

visceral leishmaniasis

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Visceral Leishmaniasis-Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn's Disease in Therapy With Anti-TNFα: A Challenging Diagnostic Case Report.

[Visceral leishmaniasis with suspected autoimmune disease: A report of 2 cases].

Visceral leishmaniasis in a multiple sclerosis patient: a rare complication of fingolimod-induced lymphopenia.